Responses to contradictory objections to biotechnology patents have in the main been applied through validity requirements and exclusions to patentability, largely with reference to morality provisions at the time of grant. This is not appropriate because the legitimacy of each issue depends upon its expression at different stages within an innovation time line. This thesis examines, with reference to three case studies, defects in the current approach of European Patent law, which arise in part due to confusion in (or fusion of) objections to inventions as opposed to exploitation. The conclusion suggests that it is not the grant of patents per se that causes difficulties but rather the way in which inventions are exploited and patent law should be focused accordingly.
| Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:664157 |
| Date | January 2008 |
| Creators | Young, J. A. |
| Publisher | University of Edinburgh |
| Source Sets | Ethos UK |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
Page generated in 0.0022 seconds